Joint Pain News and Research

RSS

Nutra Pharma manufactures first commercial batch of Cobroxin

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has completed manufacturing the first commercial batch of Cobroxin and has successfully released it for final distribution.

3 Oct 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009

Estrogen withdrawal may play a significant role in joint pain during breast cancer treatment

Aromatase inhibitors, the same drugs that have buoyed long-term survival rates among breast cancer patients, also carry side effects including joint pain so severe that many patients discontinue these lifesaving medicines. New University of Pennsylvania School of Medicine research, however, has uncovered patterns that may help clinicians identify and help women at risk of these symptoms sooner in order to increase their chances of sticking with their treatment regimen.

29 Sep 2009

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.

23 Sep 2009

Drug registration process for Nutra Pharma's pain reliever begins

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

22 Sep 2009

Postmenopausal women benefit as much from exercise as younger women

In two papers based on the experiments and published in recent months, UC Berkeley researchers report that postmenopausal women can achieve the same health benefits from regular, vigorous exercise as younger women do.

21 Sep 2009

Campaign to educate customers on chronic pain management

VitalWear, Inc. (www.vitalwear.com), a leader in thermal compression medical devices announced that it is launching a Direct Mail and Web campaign in an effort to educate customers on a recent report from the Center for Disease Control (CDC), stating that among all diabetics, 52% suffer from arthritis.

11 Sep 2009

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.

31 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

Link between collagen deficiency and osteoarthritis found in mice

Osteoarthritis (OA) and degenerative disc disease (DDD) are common, chronic musculoskeletal disorders. Both diseases cause joint pain, loss of function, and decreased quality of life for the more than 27 million OA and 59 million DDD suffers in the US. According to a 2003 Medical Expenditure Panel Survey, arthritis such as OA costs the U.S. economy nearly $128 billion per year in medical care and indirect expenses including lost wages and productivity.

27 Aug 2009

Collagen deficiency in mice causes premature development of osteoarthritis and degenerative disc disease

27 Aug 2009

FDA advisory panel recommends ban of pain medications Vicodin and Percocet

An advisory panel for the Food and Drug Administration (FDA) recently recommended limiting sales of acetaminophen products like Tylenol and also recommended banning prescription pain medications Vicodin and Percocet. This recommendation will prompt more people to change their habits and focus on joint pain remedy and pain relievers found in the natural vitamin supplements industry for arthritis treatment.

27 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

FDA approves Livalo (pitavastatin), a new cholesterol-lowering drug

The U.S. Food and Drug Administration today approved the 4 milligram maximum dose of Livalo (pitavastatin), a drug intended to improve blood cholesterol levels in persons with elevated or abnormal blood cholesterol levels.

3 Aug 2009

Inflammatory bowel disease on the rise in specific populations

Researchers are making great strides in understanding the development and treatment of inflammatory bowel disease, a chronic inflammatory condition of the digestive tract that affects more than a half million Americans, according to several studies being presented at Digestive Disease Week® 2009 (DDW®). DDW is the largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

1 Jun 2009

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Reclast (zoledronic acid) Injection has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast is already approved as a once-yearly infusion for the treatment of postmenopausal osteoporosis.

1 Jun 2009

New research nets the true economic costs of dengue fever

Researchers at Brandeis, in collaboration with several other institutions worldwide, have pinpointed for the first time the multi-country economic costs of dengue fever, the endemic and epidemic mosquito-borne illness that is a rapidly growing public health problem in tropical and sub-tropical countries.

7 May 2009

URMC expert informs lupus patients on nutrition myths, realities

With May being Lupus Awareness Month, next week University of Rochester Medical Center rheumatologist Jennifer Anolik, M.D., Ph.D., will offer a free public talk that sheds light on how sensible eating and fitness habits can help patients better manage the disease.

30 Apr 2009

Lilly granted preliminary injunction to prevent launch of generic Raloxifene

Eli Lilly and Company has announced that the U.S. District Court for the Southern District of Indiana today issued a preliminary injunction to prevent the launch of a generic version of Lilly's medicine Evista (raloxifene HCl tablets) by Teva Pharmaceuticals until the Court renders its final ruling.

22 Apr 2009